Ricciuti, B.; Lamberti, G.; Andrini, E.; Genova, C.; De Giglio, A.; Bianconi, V.; Sahebkar, A.; Chiari, R.; Pirro, M., Antibody–drug conjugates for lung cancer in the era of personalized oncology, «SEMINARS IN CANCER BIOLOGY», 2021, 69, pp. 268 - 278 [articolo]
Nebhan C.A.; Cortellini A.; Ma W.; Ganta T.; Song H.; Ye F.; Irlmeier R.; Debnath N.; Saeed A.; Radford M.; Alahmadi A.; Diamond A.; Hoimes C.; Ramaiya N.; Presley C.J.; Owen D.H.; Abou Alaiwi S.; Nassar A.; Ricciuti B.; Lamberti G.; Bersanelli M.; Casartelli C.; Buti S.; Marchetti P.; Giusti R.; Filetti M.; Vanella V.; Mallardo D.; Macherla S.; Sussman T.A.; Botticelli A.; Galetta D.; Catino A.; Pizzutilo P.; Genova C.; Dal Bello M.G.; Kalofonou F.; Daniels E.; Ascierto P.A.; Pinato D.J.; Choueiri T.K.; Johnson D.B.; Marron T.U.; Wang Y.; Naqash A.R., Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study, «JAMA ONCOLOGY», 2021, 7, pp. 1856 - 1861 [articolo]
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3), «BRITISH JOURNAL OF CANCER», 2021, 125, pp. 306 - 306 [replica/breve intervento]
Ricco G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Casadei R.; Campana D.; Lamberti G., Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading?, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 10629, pp. 10629 - 10643 [articolo]Open Access
Telo S.; Filice A.; Versari A.; Lamberti G.; Campana D.; Calabro D.; Fanti S.; Ambrosini V., Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications, «CLINICAL AND TRANSLATIONAL IMAGING», 2021, 9, pp. 423 - 438 [articolo]
Ingaldi C.; Alberici L.; Ricci C.; Campana D.; Mosconi C.; Ambrosini V.; Lamberti G.; Manuzzi L.; Minni F.; Casadei R., Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis, «UPDATES IN SURGERY», 2021, 74, pp. 991 - 998 [articolo]Open Access
Rossi R.E.; Milanetto A.C.; Andreasi V.; Campana D.; Coppa J.; Nappo G.; Rinzivillo M.; Invernizzi P.; Modica R.; David A.; Partelli S.; Lamberti G.; Mazzaferro V.; Zerbi A.; Panzuto F.; Pasquali C.; Falconi M.; Massironi S., Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy, «JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION», 2021, 44, pp. 2227 - 2234 [articolo]
Massironi S.; Campana D.; Pusceddu S.; Albertelli M.; Faggiano A.; Panzuto F.; Smiroldo V.; Andreasi V.; Rossi R.E.; Maggio I.; Torchio M.; Dotto A.; Modica R.; Rinzivillo M.; Carnaghi C.; Partelli S.; Fanetti I.; Lamberti G.; Corti F.; Ferone D.; Colao A.; Annibale B.; Invernizzi P.; Falconi M., Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study, «DIGESTIVE AND LIVER DISEASE», 2021, 53, pp. 367 - 374 [articolo]
Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A., Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution, «ANTI-CANCER DRUGS», 2021, 32, pp. 755 - 757 [articolo]Open Access
Ricci C.; Lamberti G.; Ingaldi C.; Mosconi C.; Pagano N.; Alberici L.; Ambrosini V.; Manuzzi L.; Monari F.; Malvi D.; Rosini F.; Minni F.; Campana D.; Casadei R., Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials, «CANCERS», 2021, 13, Article number: 358, pp. 1 - 14 [articolo]Open Access
Spada F.; Campana D.; Lamberti G.; Laudicella R.; Dellamano R.; Dellamano L.; Leeuwenkamp O.; Baldari S., [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2021, 49, pp. 2037 - 2048 [articolo]Open Access
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]
Ricciuti B.; Naqash A.R.; Naidoo J.; Sehgal K.; Miller A.; Kehl K.; Venkatraman D.; Sands J.; Lamberti G.; Recondo G.; Zhang J.; Macherla S.; Baig S.; Walker P.; Rangachari D.; Gainor J.F.; Costa D.B.; Rizvi N.; Sholl L.M.; Nishino M.; Henick B.; Farago A.F.; Awad M.M., Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC, «JTO CLINICAL AND RESEARCH REPORTS», 2020, 1, Article number: 100074, pp. 1 - 9 [articolo]Open Access
Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access
Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, Article number: 103119, pp. 1 - 18 [articolo]
